Abstract Number: 264 • 2018 ACR/ARHP Annual Meeting
Relationships between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus
Background/Purpose: Adverse childhood experiences (ACEs) such as abuse, neglect and domestic violence are associated with poor adult health status and immune dysregulation. The extent and…Abstract Number: 1668 • 2018 ACR/ARHP Annual Meeting
Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus
Background/Purpose: Clinical outcomes in SLE are challenging to predict. In non-SLE populations, susceptibility to adverse outcomes has been measured using a frailty index (FI), which…Abstract Number: 1711 • 2018 ACR/ARHP Annual Meeting
Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus
Background/Purpose: Measurement of treatment response in SLE clinical trials has been based on measurement of change from baseline; however a treat-to-target analysis has seldom been…Abstract Number: 2786 • 2018 ACR/ARHP Annual Meeting
Prospective Multicenter Validation Study of the Lupus Low Disease Activity State – a Treatment Target for Systemic Lupus Erythematosus
Background/Purpose: The adoption of treat to target approaches for Systemic Lupus Erythematosus (SLE) requires the definition of a target state validated for improved patient outcomes.…Abstract Number: 2930 • 2018 ACR/ARHP Annual Meeting
Prospective Comparison of Remission and Lupus Low Disease Activity State – Effect on Disease Outcomes in Systemic Lupus Erythematosus
Background/Purpose: The Definitions of Remission in SLE (DORIS) group has proposed multiple definitions of remission, but these are infrequently attained and have not previously been…Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…Abstract Number: 2989 • 2014 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus
Background/Purpose: Patient reported outcomes (PRO) are important to understand, educate, manage and follow patients with systemic lupus erythematosus (SLE). Lupus Impact Tracker (LIT) is a…Abstract Number: 2634 • 2014 ACR/ARHP Annual Meeting
A Signal of Improvement in Lupus Disease Activity at 3 Months Predicts Further Valid Improvement at 6 Months
Background/Purpose: In patients with active disease, physicians look for an early signal in response to treatment to guide their therapeutic decisions. Systemic Lupus…Abstract Number: 1657 • 2014 ACR/ARHP Annual Meeting
Does Advanced Age Influence the Type of Renal Injury and the Prognosis of Lupus Nephritis?
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that usually affects young people. Several reviews have shown that age may have an effect on…Abstract Number: 713 • 2014 ACR/ARHP Annual Meeting
Lupuspro Is Responsive to Changes in Disease Activity over Time
Background/Purpose: Patient reported outcome (PRO) tools are important to understand, educate, manage, and follow patients with systemic lupus erythematosus (SLE). Disease targeted PRO for SLE…Abstract Number: 2508 • 2013 ACR/ARHP Annual Meeting
Clinical and Serological Discordance In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
Background/Purpose: Anti-DNA antibodies and serum complement levels are considered important biomarkers for disease activity in SLE. Despite this many SLE patients present serologically active (positive…Abstract Number: 632 • 2012 ACR/ARHP Annual Meeting
The Effects of Co-Existing Proliferative Histopathology On Membranous Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) affects up to 60% of SLE patients and is worse in minority communities. Traditionally membranous LN confers a better prognosis than…Abstract Number: 2617 • 2012 ACR/ARHP Annual Meeting
Outcomes Associated with Belimumab in Black/African American Patients with Systemic Lupus Erythematous in Clinical Practice Settings in the United States
Background/Purpose: Effectiveness of belimumab in black/African American (AA) patients (pts) with Systemic Lupus Erythematous (SLE) is yet to be adequately demonstrated. The objective of this…Abstract Number: 1417 • 2012 ACR/ARHP Annual Meeting
Favorable Response to Belimumab At Three Months
Background/Purpose: Belimumab (Benlysta) is a monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the use…Abstract Number: 1418 • 2012 ACR/ARHP Annual Meeting
Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI
Background/Purpose: Disease activity measures used in SLE clinical studies, including the SLEDAI (SLE Disease Activity Index) and BILAG (British Isles Lupus Assessment Group) index are…